Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

4123 Background: Both Folfirinox and Nab-paclitaxel plus Gemcitabine showed a benefit in terms of survival in first-line treatment of metastatic pancreatic adenocarcinoma (MPA) when compared to gemcitabine. It could be of interest to use them consecutively, knowing that there is currently no standard for 2nd line treatments for MPA and that median Progression free survival (PFS) is consistently less than 4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of gemcitabine plus Nab-paclitaxel after Folfirinox failure in MPA. Methods: From February 2013 to July 2014, all consecutive patients (pts) from 12 French centers treated by Nab-paclitaxel plus Gemcitabine for a histologically proven MPA after failure of Folfirinox were prospectively recorded. Nab-paclitaxel plus Gemcitabine was delivered on days 1, 8, and 15 every 4 weeks, as previously reported, until disease progression, patient refusal or unacceptable toxicity Results: Nab-paclitaxel plus Gemcitabine was adm...